About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
Akebia Therapeutics image

Akebia Therapeutics

Rank#8741
Market Cap253.75M
CountryUnited States
Summary
History
Mission
Vision
References
Summaryarrow
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Historyarrow

Akebia Therapeutics was founded in 2007 by Marc Otte, an experienced pharmaceutical executive, and Doug Harker, a noted biomedical entrepreneur and angel investor. The company was initially focused on the discovery and development of novel treatments for anemia. Over the course of the following four years, Akebia secured financing from strategic partners, acquired novel assets and built a world-class development and commercialization team. In 2014, Akebia secured a new round of financing, bringing its total investment to date to more than $100 million.

Missionarrow
Akebia’s mission is to develop and commercialize novel therapeutics that leverage hypoxia-inducible factor biology to address unmet medical needs in patients with serious kidney diseases.
Visionarrow
Our vision is to be a leader in the translation of innovative medical breakthroughs into therapeutics that have the potential to transform the lives of patients with serious kidney diseases.
Referencesarrow

https://in.investing.com/equities/akebia-ther

https://finance.yahoo.com/quote/AKBA/profile?p=AKBA

https://www.crunchbase.com/organization/akebia-therapeutics

https://companiesmarketcap.com/

https://www.akebia.com

Share

Leadership team
M
Mr. John P. Butler MBA (CEO, Pres & Director)
M
Mr. David A. Spellman (Sr. VP, CFO & Treasurer)
M
Mr. Michel Dahan (Sr. VP & COO)
Products / Services
Biotechnology, Health Care, Therapeutics
Number of Employees
100 - 500
Address
Cambridge, Massachusetts, United States
Established
2007-01-01
Company Registration
SEC CIK number: 0001517022
Revenue
100M - 500M
Traded as
AKBA
Website
https://www.akebia.com
Social Media
linkedin
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo